The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells

Leukemia

Volumn 16, Issue 7, 2002, Pages 1362-1371

  van de Donk, N W C J ^a   Kamphuis, M M J ^a   Lokhorst, H M ^a   Bloem, A C ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Apoptosis; HMG CoA reductase; Isoprenylation; Lovastatin; Multidrug resistance; Multiple myeloma

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; DEXAMETHASONE; DOXORUBICIN; GLYCOPROTEIN P; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; MELPHALAN; MEVALONIC ACID; MEVINOLIN; MULTIDRUG RESISTANCE PROTEIN; PREDNISONE; PROTEIN BAX; PROTEIN BCL 2; RAS PROTEIN; VINCRISTINE;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL DEATH; CELL LINE; CELL MEMBRANE; CELL PROLIFERATION; CELL VIABILITY; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; CYTOSTASIS; DRUG CYTOTOXICITY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; INCUBATION TIME; ISOPRENYLATION; MALE; MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; SAMPLE; SIGNAL TRANSDUCTION;

EID: 0036045450     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402501     Document Type: Article

References (54)

1. Regulation of the mevalonate pathway
2. New insights into the interaction of Ras with the plasma membrane
3. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity
4. Protein prenylation, et cetera: Signal transduction in two dimensions
5. Ras proteins: Recent advances and new functions
6. Targeting the Ras signaling pathway: A rational, mechanism-based treatment for hematologic malignancies?
7. Molecular signals in anti-apoptotic survival pathways
8. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
9. Regulation of proliferation and Ras localization in transformed cells by products of mevalonate metabolism
10. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line
11. Cell cycle-specific effects of lovastatin
12. Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N'-bis(2-chloroethyl)-N-nitrosourea and beta-interferon on human glioma cells
13. In vivo enhanced antitumor activity of carmustine [N,N'-bis(2-chloroethyl)-N-nitrosourea] by simvastatin
14. Potentiated anti-tumour effects of cisplatin and lovastatin against MmB16 melanoma in mice
15. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells
16. Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis
17. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac
18. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice
19. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach
20. Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells
21. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering
22. Interleukin-6 in human multiple myeloma
23. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade
24. Multiple myeloma: Increasing evidence for a multistep transformation process
25. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors
26. Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6
27. Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan
28. Effect of inhibition of cholesterol synthetic pathway on the activation of Ras and MAP kinase in mesangial cells
29. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin
30. Long-term bone marrow cultured stromal cells regulate myeloma tumour growth in vitro: Studies with primary tumour cells and LTBMC-dependent cell lines
31. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma
32. Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells
33. Idarubicin overcomes P-glycoprotein-related multidrug resistance: Comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines
34. Immunoglobulin production by human peripheral lymphocytes induced by anti-C3 receptor antibodies
35. Coligation of ICAM-1 (CD54) and membrane IgM negatively affects B cell receptor signaling
36. Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells
37. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer
38. Drug resistance in multiple myeloma: Approaches to circumvention
39. P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD
40. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukemia Group of the EORTC and the HOVON
41. P-glycoprotein expression in human plasma cell myeloma: Correlation with prior chemotherapy
42. Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma
43. Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma
44. Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-xL
45. Expression of BAX in plasma cell dyscrasias
46. Effects of lovastatin on a human myeloma cell line: Increased sensitivity of a multidrug-resistant subline that expresses the 170 kDa P-glycoprotein
47. HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: Lovastatin specifically targets P-glycoprotein-expressing cells
48. Increased sensitivity of multidrug-resistant myeloid leukemia cell lines to lovastatin
49. Differentiation factors, including nerve growth factor, fibroblast growth factor, and interleukin-6, induce an accumulation of an active Ras.GTP complex in rat pheochromocytoma PC12 cells
50. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: Analysis of the Eastern Cooperative Oncology Group Phase III Trial
51. Ras oncogene mutation in multiple myeloma
52. p53 and RAS gene mutations in multiple myeloma
53. Lovastatin inhibits proliferation of pancreatic cancer cell lines with mutant as well as with wild-type K-ras oncogene but has different effects on protein phosphorylation and induction of apoptosis
54. Staging and kinetics of multiple myeloma